Image Source: Pixabay

The 6 psychedelic-compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were up 2.4% in price last week, on average, verses being down 2.6% the previous week, and are now down 0.01% MTD. They are ranked below in descending order as to their performances last week week and MTD.

1. Incannex Healthcare (IXHL): up 6.0% last week; down 2.8% MTD
   • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
   • has a *Market Capitalization of $78M
   • has a **Short Interest of: NA
   • has a ***Forward Price-to-Sales of 1712 
2. GH Research (GHRS): up 5.0% last week; down 1.2% MTD
   • is primarily focused on the use of ****mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
   • has a Market Capitalization of $542
   • has a Short Interest of 11.3%
   • has a Forward Price-to-Sales of: NM 
3. Mind Medicine (MNMD): up 4.5% last week; up 0.5% MTD
   • is primarily focused on the use of LSD and MNMA. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • has a Market Capitalization of $171M
   • has a Short Interest of 8.9%
   • has a Forward Price-to-Sales of: NM 
4. Atai (ATAI): up 1.4% last week; down 5.2% MTD
   • focused on the use of ketamine, DMT and ibogaine.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • has a Market Capitalization of $241
   • has a Short Interest of 3.1%
   • has a Forward Price-to-Sales of 1191
5. Compass Pathways (CMPS): down 0.4% last week; up 4.0% MTD
   • focused on the use of psilocybin (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
   • has a Market Capitalization of $454M
   • has a Short Interest of 19.2%
   • has a Forward Price-to-Sales of: NM 
6. Seelos (SEEL): down 9.8% last week; down 15.6% MTD
   • focused on the use of ketamine. Go here for much more extensive information on Ketamine.
   • has a Market Capitalization of $119M
   • has a Short Interest of 4.9%
   • has a Forward Price-to-Sales of 88 

* Market Capitalization is the total value of a company's outstanding shares of stock and is a measurement of a company's size. 

** A high short interest signals that investors have become more bearish and may be getting ready to sell and, as such, that it may be time to liquidate a long position.

***The P/S ratio (PSR) describes how much someone must pay to buy one share of a company relative to how much that share generates in revenue for the company. and, as such, determines whether its stock is cheap or overpriced in comparison to its peers. While the ideal ratio depends on the company and industry, the ratio is typically good when the value falls between one (1)  and two (2) and a ratio of less than one (1`) is even better.

****10 Psychedelic Substances And The 36 Companies Researching Them describes each of the psychedelic-based compounds mentioned in this article.

Summary

As mentioned in the introduction, our munKNEE Psychedelic Drug Stocks Index was up 2.4% last week verses being down 2.6% the previous week and is now down 0.1% MTD.

If you are interested in this category, consider the  AdvisorShares Psychedelic ETF (PSIL) of 23 such stocks, of which the majority have market capitalizations of less than $50M. It is down 2.2% this week and is now down 4.4% MTD.

More By This Author:

Conservative "Cannabis" Stock Index Unchanged In September
Canada's Largest Cannabis LPs Up 26%, On Average, MTD
These 9 AI Stocks Are Up Over 100% YTD